 TORRANCE, Calif., June 15, 2021 PRNewswire -- Emmaus Life Sciences, Inc. OTC: EMMA, a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today it has received confirmation from the Swiss Agency for Therapeutic Products Swissmedic of Emmaus application for Marketing Authorization MA for Endari in Switzerland. 